Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Multicenter, Randomized, Double-masked, Parallel-group, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT03845582 is registered in ClinicalTrials.gov with Alkeus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03845582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03845582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Multicenter, Randomized, Double-masked, Parallel-group, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-related Macular Degeneration
Lead sponsor
Alkeus Pharmaceuticals, Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
May 7, 2019
Completion date
June 30, 2024
Enrollment
200 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

age related macular degeneration, amd, atrophy, geographic, geographic atrophy